

News Releases

All Years

Search

Go

[Advanced Search](#)

AUG 13, 2024

Inhibrx Biosciences Reports Second Quarter 2024 Financial Results and Recent Corporate Highlights

MAY 24, 2024

Inhibrx Inc. Stockholders Approve Sale of INBRX-101 to Sanofi

MAY 10, 2024

Inhibrx, Inc. Announces Updated When-Issued Trading Date for Anticipated Spin-Off

MAY 8, 2024

Inhibrx, Inc. Announces Record Date and Expected Distribution Time for Anticipated Spin-Off and the Expected Merger Effective Time for Anticipated Merger

FEB 28, 2024

Inhibrx Reports Fourth Quarter and Fiscal Year 2023 Financial Results

JAN 23, 2024

Inhibrx Announces Sale of INBRX-101 to Sanofi for an aggregate value of up to \$2.2B

NOV 9, 2023

Inhibrx Reports Third Quarter 2023 Financial Results and Recent

Inhibrx Reports Third Quarter 2023 Financial Results and Recent Corporate Highlights

NOV 2, 2023

Inhibrx Announces Preliminary Data from the Phase 1 Trial of INBRX-109 for the Treatment of Ewing Sarcoma

OCT 18, 2023

Inhibrx Announces Participation in Upcoming Scientific Conferences

AUG 29, 2023

Inhibrx Announces \$200 Million Private Placement Financing

Show per
page

[«](#) [1](#) [2](#) [3](#) [4](#) [5](#) [6](#) [7](#) [8](#) [»](#)



<https://inhibrx.investorroom.com/news-releases?l=10&o=20>